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A B S T R A C T
Since 1996, the Dutch Working Party on Antibiotic Policy
(Stichting Werkgroep AntibioticaBeleid, SWAB) has been
developing national guidelines for the use of antibiotics
in hospitalised adult patients. As a result of both an
inventory of the wishes of the users of these guidelines
and the recently developed criteria for evidence-based
guideline development, we have revised our format for
the development of SWAB guidelines. By involving the
members of the relevant professional societies and giving
them the opportunity to comment on the guidelines at an
early stage, we are aiming for a successful implementation
of the guidelines in the hospitals.
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I N T R O D U C T I O N
In this issue of the Netherlands Journal of Medicine you
will find the revised SWAB guideline for community-
acquired pneumonia.1 The Dutch Working Party on
Antibiotic Policy (Stichting Werkgroep AntibioticaBeleid,
SWAB) was founded in 1996 as an initiative of the Dutch
Society for Medical Microbiology (NVMM), the Dutch
Society for Infectious Diseases (VIZ) and the Dutch
Association of Hospital Pharmacists (NVZA). Its major
goal is to contribute to the containment of antimicrobial
resistance and the expanding costs of the use of antibiotics.
This is achieved by optimising the use of antibiotics by
means of guideline development, education, and surveil-
lance of antibiotic use and resistance.
In 2001, the SWAB was designated by the Ministry of
Health to coordinate the surveillance of antibiotic resistance.
In addition, the SWAB coordinates the surveillance of the
use of antibiotics. Nethmap 2003, the first report with
new information about consumption of antimicrobial
agents and antimicrobial resistance among medically
important bacteria in the Netherlands, was presented in
April 2003, during the SWAB symposium 2003 in Utrecht.2
Nethmap is updated annually (http://www.swab.nl professional).
S W A B  G U I D E L I N E S
Since its conception, the SWAB has developed national
guidelines for the use of antibiotics, which are aimed at
the hospitalised adult patient. Guidelines are published in
a Dutch medical journal (Nederlands Tijdschrift voor
Geneeskunde).3-7 Until now, the contents of these guidelines
were prepared by a writing committee, consisting of five to
ten experts. A proposal for the guideline was prepared by
this committee and sent out for review to approximately
30 experts (medical microbiologists, infectious diseases
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specialists, hospital pharmacists and medical specialists
relevant to the specific topic). Based on their comments, 
a final guideline was prepared. 
In 2001, a survey among hospital antibiotic policy com-
mittees revealed that the majority of respondents were
aware of SWAB’s guidelines, but it was suggested that
the guideline concept should be made more broadly
available, e.g. on the internet, and with a clearer method
for grading the strength of the evidence on which the
guideline was based.8
D E V E L O P M E N T  O F  G U I D E L I N E S  –
R E C E N T  I N S I G H T S
As the number of clinical practice guidelines increases,
there is a growing need to ensure that they satisfy certain
minimum requirements. The AGREE (Appraisal of
Guidelines, REsearch and Evaluation) collaboration has
developed and validated an instrument that can be used
to improve the quality of guideline development.9 Six
pivotal criteria of high-quality clinical practice guidelines
have been identified: 
- Scope and purpose: the overall objective, clinical
questions, and target population should be specified.
- Stakeholder involvement: the composition, discipline,
and expertise of the guideline development group
should be specified. Target users should be defined.
- Rigour of development: the search strategy, inclusion/
exclusion criteria for selecting the evidence, and the
methods used to formulate the recommendations should
be given. The recommendations should be externally
reviewed before publication, and the information
should be updated regularly.
- Clarity and presentation: the recommendations should
be specific and unambiguous, different options should
be presented, and key recommendations should be
easily identifiable. 
- Applicability: the organisational changes and cost
implications of applying the recommendations should
be discussed. Review criteria to monitor the use of the
guidelines should be given. 
- Editorial independence: the final recommendations
should be independent of the views or interests of the
funding body, and conflicts of interests should be
stated. 
A review of the development of clinical practice guidelines,
especially in the field of infectious diseases, was pub-
lished recently in this journal.10 A distinct and specific
feature of guidelines for infectious diseases is that local
epidemiology and resistance data must be taken into
account. 
S W A B  G U I D E L I N E S :  N E W  F O R M A T  
As a result of both the survey of the users of the guide-
lines and the introduction of the evidence-based guideline
development mentioned above, we recently revised the
procedures for the development of SWAB guidelines
(http://www.swab.nl  professionals  richtlijnen). Crucial elements in these procedures are: 
- For each guideline, a writing committee is composed
of members of all professional organisations involved:
the Dutch Society for Medical Microbiology (NVMM),
the Dutch Society for Infectious Diseases (VIZ) and
the Dutch Association of Hospital Pharmacists
(NVZA), the Dutch College of General Practitioners
(NHG), and any other specialities that are relevant for
the specific guideline under development. 
- One of the first steps of the writing committee is to
establish the main questions that should be addressed.
Based on these questions, a systematic search of the
literature is performed, according to the principles for
literature searches described earlier.9,11 This results in
a systematic review, in which the literature is graded
and the strength of the resulting conclusions is graded
according to the level of evidence. Based on this sys-
tematic review, a draft guideline is proposed by the
writing committee. 
- This draft guideline is made available to all members of
the professional societies involved in the development
of the guideline. They can access the concept guideline
through the SWAB website (www.swab.editline.nl)
and the websites of the respective societies, and they
can comment on the proposal through this website.
Based on these comments, the writing committee
finalises the guideline. 
- As the hospitalised patients are the target population,
local antibiotic policy committees remain the target
users of the guidelines, because they are essential for
the interpretation, the adaptation to local resistance
patterns and policies, and the implementation of
infectious diseases guidelines.10
- The final systematic review will be published in the
Netherlands Journal of Medicine, or in other journals if
applicable, for instance in the case of endocarditis, in
Hartbulletin. A shortened version of the guideline
will, as before, be submitted for publication in Het
Nederlands Tijdschrift voor Geneeskunde.
In conclusion, this new procedure meets the criteria for
evidence-based guideline development. By involving the
membership of the relevant professional societies, and
giving them the opportunity to comment on the guide-
lines at an early stage, we can also aim for a successful
implementation of the guidelines in the hospitals. The
new SWAB guidelines that have been fully developed
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according to the above-mentioned procedures will be
published in the coming year: guidelines on community-
acquired pneumonia, acute infectious diarrhoea, and
urinary tract infections. 
N O T E
The authors are Board Members of the Dutch Working
Party on Antibiotic Policy (Stichting Werkgroep
AntibioticaBeleid, SWAB).
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